

Part II requires respondents to possess competent and reliable scientific evidence to substantiate claims that any smoking-cessation or cigarette-modification product: (A) reduces the amount of nicotine, tar, carbon monoxide, or any other component of cigarette smoke that smokers get from smoking a cigarette; (B) is effective in enabling or helping smokers to quit smoking; (C) reduces the risk of smoking-related health problems for smokers who continue to smoke; (D) reduces the amount of nicotine, tar, carbon monoxide, or any other component of cigarette smoke that smokers get without changing a cigarette's taste or draw; (E) is effective in enabling or helping smokers to quit smoking without withdrawal symptoms; or (F) provides immediate health benefits, such as reduced congestion, coughing or windedness, for smokers who continue to smoke. Part II also requires respondents to possess competent and reliable scientific evidence to substantiate claims that smokers using any such product will not compensate for the product's effects by increasing the number of cigarettes they smoke per day.

Part III requires respondents to possess competent and reliable scientific evidence to substantiate any performance, benefit or efficacy claims for smoking-cessation or cigarette-modification products.

Part IV prohibits the respondents from misrepresenting the existence, contents, validity, results, conclusions, or interpretations of any test or study.

Part V requires respondents either to possess competent and reliable scientific evidence to substantiate claims that any endorsement reflects the typical or ordinary experience of consumers who use the product; or to clearly and prominently disclose either: a) what the generally expected results would be, or b) that consumers should not expect to experience similar results.

Part VI requires respondents to send a postcard to identifiable past purchasers of PhaseOut notifying them of the Commission's action in this case and advising them that PhaseOut has *not* been proven to reduce the risk of smoking-related diseases or to make cigarettes "safer." Part VI also requires respondents to send a letter to their purchasers for resale requesting the names and addresses of their customers and notifying them that if the purchasers for resale do not stop using advertising and promotional materials containing claims covered by this order, the respondents are required to stop doing business with them. Part VII requires the respondents to maintain for

five years copies of all communications with consumers and purchasers for resale pursuant to the terms of Part VI.

The proposed order also requires respondents to maintain materials relied upon to substantiate the claims covered by the order, to distribute copies of the order to certain current officers and employees, to notify the Commission of any changes in corporate structure that might affect compliance with the order, and to file one or more reports detailing compliance with the order. The order also contains a provision stating that it will terminate after twenty (20) years absent the filing in federal court, by either the United States or the FTC, of a complaint against the respondents alleging a violation of the order.

The purpose of this analysis is to facilitate public comment on the proposed order, and it is not intended to constitute an official interpretation of the agreement and proposed order, or to modify any of their terms.

Donald S. Clark,
Secretary.

[FR Doc. 96-30943 Filed 12-4-96; 8:45 am]
BILLING CODE 6750-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Research Resources; Notice of Meetings

Pursuant to Pub. L. 92-463, notice is hereby given of the meetings of the National Center for Research Resources Initial Review Group and the Scientific and Technical Review Board on Biomedical and Behavioral Research Facilities for February 1997. These meetings will be open to the public as indicated below, to discuss program planning; program accomplishments; administrative matters such as previous meeting minutes; the report of the Director, National Center for Research Resources (NCRR); review of budget and legislative updates; and special reports or other issues relating to committee business. Attendance by the public will be limited to space available.

These meetings will be closed to the public as indicated below in accordance with provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, for the review, discussion and evaluation of individual grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with

the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Ms. Maureen Mylander, Public Affairs Officer, NCRR, National Institutes of Health, 1 Rockledge Center, Room 5146, 6705 Rockledge Drive, MSC 7965, Bethesda, Maryland 10892-7965, (301) 435-0888, will provide summaries of meetings and rosters of committee members. Other information pertaining to the meetings can be obtained from the Scientific Review Administrator indicated. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact the Scientific Review Administrator listed below, in advance of the meeting.

Name of Committee: National Center for Research Resources Initial Review Group—Research Centers in Minority Institutions Review Committee.

Dates of Meeting: February 10, 1997.

Place of Meeting: The Bethesda Ramada, Ambassador II Room, 8400 Wisconsin Avenue, Bethesda, MD 20814, (301) 654-1000.

Open: February 10, 8:30 a.m.—10:30 a.m.

Closed: February 10, 10:30 a.m. until adjournment.

Scientific Review Administrator: Dr. John Lymangrover, National Institutes of Health, 1 Rockledge Center, Room 6018, 6705 Rockledge Drive, MSC 7965, Bethesda, MD 20892-7965, Telephone: (301) 435-0820.

Name of Committee: National Center for Research Resources Initial Review Group—Comparative Medicine Review Committee.

Date of Meeting: February 23-25, 1997.

Place of Meeting: The Latham Hotel, Washington/Jefferson Conference Room, 3000 M Street, N.W., Washington, DC 20007 (202) 726-5000.

Closed: February 23, 6:30 p.m. until recess.

Open: February 24, 8:30 a.m.—10:00 a.m.

Closed: February 24, 10:00 a.m. until adjournment.

Scientific Review Administrator: Dr. Raymond O'Neil, National Institutes of Health, 1 Rockledge Center, Room 6018, 6705 Rockledge Drive, MSC 7965, Bethesda, MD 20892-7965, Telephone: (301) 435-0814.

Name of Committee: Scientific and Technical Review Board on Biomedical and Behavioral Research Facilities.

Date of Meeting: February 25, 1997.

Place of Meeting: Gaithersburg Hilton, Darnestown Room, 620 Perry Parkway, Gaithersburg, MD 20877, (301) 977-8900.

Open: February 25, 8:00 a.m.—10:00 a.m.

Closed: February 25, 10:00 a.m. until adjournment.

Scientific Review Administrator: Dr. Jill Carrington, Dr. D.G. Patel, National Institutes of Health, 1 Rockledge Center, Room 6018, 6705 Rockledge Drive, MSC 7965, Bethesda, MD 20892-7965, Telephone: (301) 435-0822.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, Laboratory Animal Sciences and Primate Research; 93.389;

Research Centers in Minority Institutions; 93.167, Research Facilities Improvement Program; 93.214 Extramural Research Facilities Construction Projects, National Institutes of Health)

Dated: November 27, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96-30952 Filed 12-4-96; 8:45 am]

BILLING CODE 4140-01-M

National Center for Research Resources; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: NCRR Initial Review Group—General Clinical Research Centers Review Committee.

Dates of Meeting: February 12-14, 1997.

Time: 8:00 a.m.—until adjournment.

Place of Meeting: Hyatt Regency, Bethesda, Potomac/Patuxent Conference Room, One Bethesda Metro Center, Bethesda, MD 20815, Telephone: (301) 657-6406.

Scientific Review Administrator: Dr. Charles Hollingsworth, National Institutes of Health, 1 Rockledge Center, Room 6018, 6705 Rockledge Drive, MSC 7965, Bethesda, MD 20892-7965, Telephone: (301) 435-0818.

Purpose/Agenda: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program No. 93.333 Clinical Research, National Institutes of Health, HHS)

Dated: November 26, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96-30957 Filed 12-4-96; 8:45 am]

BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Heart, Lung, and Blood Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: SCOR in Molecular Medicine and Atherosclerosis.

Date: December 20, 1996.

Time: 8:00 a.m.

Place: DoubleTree Hotel, 1750 Rockville Pike, Rockville, Maryland 20852.

Contact Person: Eric H. Brown, Ph.D., Two Rockledge Center, Room 7204, 6701 Rockledge Drive, Bethesda, MD 20892-7924, (301) 435-3541.

Purpose/Agenda: To review and evaluate grant applications.

This meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to this meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle. (Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: November 26, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96-30958 Filed 12-4-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Institute of Mental Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: December 2, 1996.

Time: 2 p.m.

Place: Parklawn, Room 9C-18, 5600 Fishers Lane, Rockville, MD 20857.

Contact Person: Salvador H. Cuellar, Parklawn, Room 9C-18, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443-4868.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program Numbers 93.242, 93.281, 93.282)

Dated: November 29, 1996.

Anna Snouffer,

Committee Management Specialist, NIH.

[FR Doc. 96-30950 Filed 12-2-96; 12:02 pm]

BILLING CODE 4140-01-M

National Institute on Deafness and Other Communication Disorders; Notice of Meeting Cancellation

Notice is hereby given of the cancellation of the meeting of the National Institute on Deafness and Other Communication Disorders Special Emphasis Panel, December 10, 1996, which was to have taken place as a telephone conference call originating in Room 400C Executive Plaza South, 6120 Executive Blvd., Rockville, Maryland 20852, which was published in the Federal Register on November 27, 1996, 61 FR 60291.

This meeting is being cancelled due to the National Institute on Deafness and Other Communication Disorders' cancellation of the solicitation RFP-NIH-DC-96-03.

Dated: December 2, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96-30951 Filed 12-4-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute on Deafness and Other Communication Disorders; Notice of Closed Meeting of the Advisory Council and Its Planning Subcommittee

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the National Deafness and Other Communication Disorders Advisory Council and its Planning Subcommittee on January 22-23, 1997, at the National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland. Both meetings will take place as telephone conference calls. The Planning Subcommittee will originate in Conference Room 7, Building 31. The meeting of the full Council will originate in Conference Room 6, Building 31.

In accordance with the provisions set forth in Secs. 552b(c)(4) and 552b(c)(6), Title 5, United States Code and Sec. 10(d) of Pub. L. 92-463, the meeting of the Planning Subcommittee on January 22 will be closed to the public from 1 p.m. to adjournment. The meeting of the full Council will be closed to the public on January 23 from 1 pm until adjournment. The meetings will include the review, discussion, and evaluation of individual grant applications. The applications and the discussions could